MISTLETOE LECTIN SYNERGIZES WITH PACLITAXEL IN HUMAN SK-Hep1 HEPATOCARCINOMA CELLS

Abstract

The effect of mistletoe lectin I (ML-I), an inhibitor of ribosomal protein synthesis, on the in vitro cytotoxicity of a clinically important anticancer drug, paclitaxel, was studied on cultured human hepatocarcinoma SK-Hep1 cells using the microculture tetrazolium test. The interaction between these two agents was analyzed for true synergism using the ED50 isobologram. Synergism was observed in the simultaneous treatment of the cells with ML-I in combination with paclitaxel. In addition, 24-h exposure of the cells to a non-toxic dose of ML-I and lower toxic doses of paclitaxel in combination resulted in apoptotic cell death, as observed by agarose-gel electrophoresis of low-molecular-weight DNA and DNA flow cytometry. Thus, the results presented here indicate the potential clinical usefulness of ML-I combination therapy with paclitaxel.

Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment

“…Variability in effect size by different extracts (Wanwimolruk et al 2009 ) Possible: Hepatotoxic effects (García-Cortés et al 2016 ; Mazzanti et al 2009 ). Caution when combining with drugs acting hepatotoxic such as cytarabine, daunorubicin, doxorubicin, epirubicin, gemcitabine, methotrexate, paclitaxel, topotecan, tretinoin, and others Hawthorn Possible: Interactions with bortezomib, cyclophosphamide, docetaxel, irinotecan, vincristine, and others by induction of CYP3A4 (JANSSEN-CILAG INTERNATIONAL NV 2019 ; Petri 2017 ; Xu et al 2011 ) Lutein Unlikely Mistle Likely: Increase in effects of paclitaxel by inhibiting ribosomal protein synthesis (Pae et al 2001 ) Possible: Induction of hypersensitivity and interactions with immunotherapy by unspecific activation of the immune system (Zeller et al 2013 ) Unlikely: Interactions regarding CYP3A4 (Engdal and Nilsen 2009 ; Schink and Dehus 2017 ) Mushrooms (Medicinal mushrooms) Possible: Cytochrome (CYP) interactions depending on the different ingredients. E.g., CYP2D6 induction by AHCC (Shitake mushrooms) leading in reduction in effects of doxurubicin (Mach et al 2008 ) Possible: Induction of hypersensitivity and interactions with immunotherapy by unspecific activation of the immune system (Zeller et al 2013 ) Nigella sativa Possible: Interactions with bortezomib, cyclophosphamide, docetaxel, irinotecan, vincristine, and others by inhibition of CYP2D6 and CYP3A4 (Al-Jenoobi et al 2010 ; JANSSEN-CILAG INTERNATIONAL NV 2019 ; Petri 2017 ) OPC (Oligomeric proantho-cyanidins) Possible: Reduction in cytotoxic effects of cancer therapy.…”

Potential risks associated with traditional herbal medicine use in cancer care: A study of Middle Eastern oncology health care professionals

“…A total of 29 of the 44 herbal products identified were associated with safety‐related concerns (65.9%) (Table ) . These were grouped according to 3 predominant themes: 1) potentially harmful herb‐drug interactions with a reduction in bioavailability (and thus efficacy) of anticancer agents, or increased drug levels with increased toxicity (15 herbs; 34.1%); 2) directly toxic effects of herbal compounds and metabolites (18 herbs; 40.9%); and 3) enhanced anticancer effects of conventional treatment through either synergy with herbal components or chemosensitization of cancer cells, thereby increasing the response to treatment (7 herbs; 15.9%).…”

“…with doxorubicin‐related apoptosis in the MCF‐7 breast carcinoma cell line as well as with etoposide and doxorubicin in drug‐resistant smallcell lung carcinoma cells; and finally, Viscum album L . with paclitaxel in human SK‐hep1 hepatocarcinoma cells . Herbal compounds also have been found to attenuate the anticancer effects of chemotherapy (eg, inhibition of etoposide on the MCF‐7 breast cancer cells in the presence of curcumin) and promote cancer progression (eg, Thymus vulgaris on estrogen receptor activity) …”

“…Increased cell death has been observed with Curcuma longa L. in patients with cisplatinresistant lung cancer cells 83 ; Ganoderma lucidum with doxorubicin in HeLa cells 84 and doxorubicin-resistant leukemic cell lines 85 ; Linum usitatissimum L. enhancing the antitumor effects of trastuzumab in breast cancer cell lines 86 ; Nigella sativa L. with gemcitabine and oxaliplatin in pancreatic cancer cells 87 ; Panax ginseng metabolites (Rh2 ginsenosides) with paclitaxel in multidrug-resistant breast cancer cells 88 ; Silybum marianum L. with doxorubicin-related apoptosis in the MCF-7 breast carcinoma cell line 89 as well as with etoposide and doxorubicin in drug-resistant smallcell lung carcinoma cells 90 ; and finally, Viscum album L. with paclitaxel in human SK-hep1 hepatocarcinoma cells. 91 Herbal compounds also have been found to attenuate the anticancer effects of chemotherapy (eg, inhibition of etoposide on the MCF-7 breast cancer cells in the presence of curcumin) 92 and promote cancer progression (eg, Thymus vulgaris on estrogen receptor activity). 93…”

Density functional theoretical study on attachment sites of Mg2+ and Ca2+ and metal ion affinity to Crenulatin molecule

“…Recently, many biological activities have been reported for Rhodiola species such as adaptogenic, antihypoxia, antifatigue, antioxidant, antiarrhythmic, cardioprotection, anticancer, and enhancement in learning and memory [1][2][3][4][5][6][7][8][9]. The study of Rhodiola species is considered a subject of great interest.…”